Susan Galbraith, AstraZeneca EVP of oncology R&D (Rachel Kiki for Endpoints News)
May 17, 2023 07:34 AM EDT
Pharma

As­traZeneca push­es Tagris­so-chemo com­bo fol­low­ing pos­i­tive pro­gres­sion-free sur­vival da­ta

Katherine Lewin

News Reporter

As­traZeneca’s EGFR in­hibitor Tagris­so (os­imer­tinib) could be on its way to adding an­oth­er lung can­cer in­di­ca­tion af­ter the com­pa­ny said on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Chi­na’s biotech mar­ket is stag­ing a come­back that US biotech can on­ly wish for

With aims to be­come a 'gen­er­a­tional biotech,' Zealand Phar­ma hires Lil­ly vet­er­an as sci­ence chief

Large vac­cine mak­ers stand by their in­vest­ments de­spite US head­winds

Genen­tech vet launch­es ADC start­up with $20M

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times